US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

Loading ...

Overview Company News Filings

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating

MT Newswires Live

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.

Positive Outlook on Praxis Precision Medicines Amidst Phase 3 ET Program Challenges

Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment

BeOne Medicines Is Maintained at Outperform by Macquarie

Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position

Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge

MT Newswires Live

BeOne Medicines Is Maintained at Market Outperform by Citizens Capital Markets

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

ACCESS Newswire

Praxis Precision Medicines Shares Slide on Study Setback

Praxis Precision Medicines Says it Gets Recommendation From IDMC to Stop Study 1 of Essential3 Program

MT Newswires Live

Krystal Biotech's Skin Disorder Treatment Recommended by European Medicines Agency Committee

MT Newswires Live

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

AbbVie Receives Positive Opinion on Giant Cell Arteritis Therapy From European Medicines Agency

MT Newswires Live

Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs

Revolution Medicines Is Maintained at Buy by Needham

Q4 2024 Revolution Medicines Inc Earnings Call

Thomson Reuters StreetEvents

Revolution Medicines Q4 Net Loss Narrows

MT Newswires Live

Revolution Medicines Q4 2024 GAAP EPS $(1.12) Misses $(1.00) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCO/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"01-03 16:00:00 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516638546","title":"Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516638546","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516638546?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:37","pubTimestamp":1741005469,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of Buy and mean price target of $99.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","PRAX","DB"],"gpt_icon":0},{"id":"2516708635","title":"Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2516708635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516708635?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:06","pubTimestamp":1740974772,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Everest Medicines by retail investors implies that the general public has more...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limiteds-hkg1952-biggest-owners-are-retail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","01952","MDCO","BK1574"],"gpt_icon":0},{"id":"2516063643","title":"Positive Outlook on Praxis Precision Medicines Amidst Phase 3 ET Program Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2516063643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516063643?lang=en_us&edition=fundamental","pubTime":"2025-03-01 04:05","pubTimestamp":1740773118,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report) today and set a price target of $61.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-praxis-precision-medicines-amidst-phase-3-et-program-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-praxis-precision-medicines-amidst-phase-3-et-program-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","ET","BK4561","BK4590","PRAX","BK4139","BK4581","BK4588","MDCO","BK4144"],"gpt_icon":0},{"id":"2516337732","title":"Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516337732","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516337732?lang=en_us&edition=fundamental","pubTime":"2025-03-01 01:25","pubTimestamp":1740763515,"startTime":"0","endTime":"0","summary":"Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Praxis Precision Medicines (PRAX – Research Report). The associated pri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/praxis-precision-medicines-navigating-challenges-and-catalysts-in-epilepsy-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/praxis-precision-medicines-navigating-challenges-and-catalysts-in-epilepsy-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRAX","MDCO"],"gpt_icon":0},{"id":"2516452372","title":"BeOne Medicines Is Maintained at Outperform by Macquarie","url":"https://stock-news.laohu8.com/highlight/detail?id=2516452372","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516452372?lang=en_us&edition=fundamental","pubTime":"2025-03-01 01:21","pubTimestamp":1740763260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 12:21 ET (17:21 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","MDCO"],"gpt_icon":0},{"id":"2516379013","title":"Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379013?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:25","pubTimestamp":1740759939,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report) today and set a price target of $8...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-maintained-for-praxis-precision-medicines-despite-essential3-setback-focus-on-promising-pipeline-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-maintained-for-praxis-precision-medicines-despite-essential3-setback-focus-on-promising-pipeline-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRAX","MDCO"],"gpt_icon":0},{"id":"2516379157","title":"Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379157","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379157?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:16","pubTimestamp":1740759415,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of Buy and mean price target of $160.46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","PRAX"],"gpt_icon":0},{"id":"2516379667","title":"BeOne Medicines Is Maintained at Market Outperform by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379667","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379667?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:07","pubTimestamp":1740758820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 11:07 ET (16:07 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","ONC"],"gpt_icon":0},{"id":"2516379829","title":"Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379829","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379829?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:30","pubTimestamp":1740756600,"startTime":"0","endTime":"0","summary":"mRESVIA is Moderna's second approved product in the UK. CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc.  today announced that the Medicines and Healthcare products Regulatory Agency  in the UK has granted marketing authorization for mRESVIA , indicated for active immunization for the prevention of lower respiratory tract disease  caused by respiratory syncytial virus  in adults 60 years of age and older.\"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness,\" said Stéphane Bancel, Chief Executive Officer of Moderna. \"Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year.\". Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By wor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-receives-medicines-healthcare-products-153000648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4501","BK4551","BK4533","BK4532","BK4137","BK4585","BK4588","BK4534","MRNA","BK4548","BK4568","MDCO","HCSG","BK4139"],"gpt_icon":1},{"id":"2514765533","title":"Praxis Precision Medicines Shares Slide on Study Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2514765533","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514765533?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:26","pubTimestamp":1740756360,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines shares lost more than a third of their value on Friday after the clinical-stage biopharmaceutical company suffered a setback in its late-stage studies of its ulixacaltamide drug candidate for adults with essential tremor.Shares of the Boston company were recently changing hands at $40.95, down 37%.Praxis on Friday said an independent data monitoring committee determined that one of two Phase 3 studies of ulixacaltamide is unlikely to meet its primary efficacy endpoint under the parameters set by the statistical model and recommended that the study be stopped for futility.However, Praxis said it will continue both studies to completion, given their advanced state of enrollment. The company said it expects topline results from the studies in the third quarter, and that it will explore different analysis methods for the final dataset.Praxis said it will make a decision about whether the data supports seeking Food and Drug Administration approval of the drug afte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX","MDCO"],"gpt_icon":0},{"id":"2514322169","title":"Praxis Precision Medicines Says it Gets Recommendation From IDMC to Stop Study 1 of Essential3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2514322169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514322169?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:01","pubTimestamp":1740751288,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines  said Friday it received a recommendation from an independent data monitoring committee overseeing the company's study 1 of the Essential3 program of ulixacaltamide in essential tremor that the study be \"stopped for futility.\"The committee's decision was based on the possibility that the study will not meet its primary efficacy endpoint under the criteria set by the statistical model, the biopharmaceutical company added.Praxis said that the committee also \"encouraged\" it to mull other analysis methods, adding that it intends to continue both study 1 and study 2 of the program and the results are expected in Q3.Shares of the company fell 40% in recent Friday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MDCO","PRAX"],"gpt_icon":0},{"id":"2514649329","title":"Krystal Biotech's Skin Disorder Treatment Recommended by European Medicines Agency Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2514649329","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514649329?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:01","pubTimestamp":1740747688,"startTime":"0","endTime":"0","summary":"Krystal Biotech  said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended European Commission  approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa.The indication is specifically for patients with the genetic skin disorder who have mutations in the collagen type VII alpha 1 chain gene starting from birth, the company said.The opinion supports administration of the drug, also called beremagene geperpavec-svdt,  either at a clinic or at home by healthcare professionals or trained patients or caregivers, the company said.A final decision by the European Commission is expected in Q2, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EC","BK4201","BK4139","KRYS","MDCO"],"gpt_icon":0},{"id":"2514329163","title":"Praxis Precision Medicines Provides Update on Essential3 and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329163","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329163?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"BOSTON, Feb. 28, 2025  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor , an update on other therapies in development and a financial update.Results of the Planned Interim Analysis and Update on Topline Read-out for the Essential3 Program:. The EMPOWER observational study, in partnership with the Epilepsy Study Consortium, characterizing seizure burden, is ongoing with over 3,000 patients consented. Early results were shared during the Praxis scientific exhibit at the December 2024 American Epilepsy Society  Annual Meeting, demonstrating significa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/praxis-precision-medicines-provides-essential3-130000962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","LU0061475181.USD","LU1093756168.USD","BK4581","PRAX","BK4561","IE00B19Z3B42.SGD","CNS","BK4519","ET","BK4139","AES","BK4105","LU1093756325.SGD","IE0002270589.USD","BK4588","ASO","BK4135","BK4200","IE00B7SZLL34.SGD","BK4585","BK4590","IE00B19Z3581.USD","MDCO"],"gpt_icon":0},{"id":"2514329905","title":"BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329905","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329905?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:49","pubTimestamp":1740746940,"startTime":"0","endTime":"0","summary":"Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity  financing. Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management. Business combination is expected to be completed in the third quarter of 2025. The combined entity will be named BridgeBio Oncology Therapeutics  and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies. Net proceeds from the transaction are expected to provide BBOT with the capital needed to accelerate the development of three lead programs: BBO-8520, BBO-10203, and BBO-11818. BBO-8520 is a direct inhibitor of KRASG12C in both the \"ON\" and \"OFF\" states and is currently being evaluated in the Phase 1 ONKORAS-101 trial  for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 is an orally bioavailable small molecule","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-bbot-helix-124900685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","PIPE","HLXB","MDCO","BK4139"],"gpt_icon":0},{"id":"2514343944","title":"AbbVie Receives Positive Opinion on Giant Cell Arteritis Therapy From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2514343944","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514343944?lang=en_us&edition=fundamental","pubTime":"2025-02-28 17:21","pubTimestamp":1740734499,"startTime":"0","endTime":"0","summary":"AbbVie  said Friday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of its Rinvoq drug for the treatment of giant cell arteritis in adults.The positive opinion is based on results from the company's phase 3 clinical trial evaluating the efficacy and safety of the drug. The primary endpoint of sustained remission and important secondary endpoints of the study were met, AbbVie said.The company anticipates final approval from the European Commission for the product in the first half of 2025.Giant cell arteritis is an inflammatory disease that can result in blindness and stroke if left untreated, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443465.HKD","LU2468319806.SGD","LU1430594728.SGD","IE00BFTCPJ56.SGD","SG9999003800.SGD","LU1934455194.USD","LU2089984988.USD","BK4533","LU2087621335.USD","LU1291159041.SGD","BK4585","LU0114720955.EUR","LU1061106388.HKD","LU1989771016.USD","IE00B3PB1722.GBP","LU0861579265.USD","LU0965508806.USD","LU0985320562.USD","LU0029864427.USD","BK4559","LU1244550221.USD","LU1989772840.SGD","SG9999001440.SGD","LU0158827948.USD","LU0545039389.USD","LU0198837287.USD","LU0738911758.USD","MDCO","ABBV","BK4581","LU1093756168.USD","IE0002141913.USD","LU1732799900.SGD","LU0256863902.USD","LU0795875169.SGD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU0211327993.USD","BK4550","LU0310799852.SGD","LU0882574055.USD","LU1037948897.HKD","LU0943347566.SGD","BK4588","LU1267930490.SGD","BK4139","LU1057294990.SGD","LU2023251221.USD","LU0949170772.SGD","LU0203345920.USD"],"gpt_icon":0},{"id":"2514836156","title":"Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2514836156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514836156?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:52","pubTimestamp":1740707573,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. (($RVMD)) has held its Q4 earnings call. Read on for the main highlights of the call. Revolution Medicines’ recent earni...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-earnings-call-positive-progress-amid-rising-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-earnings-call-positive-progress-amid-rising-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","PRGS","RVMD"],"gpt_icon":0},{"id":"2514804838","title":"Revolution Medicines Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804838","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514804838?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:01","pubTimestamp":1740661260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 08:01 ET (13:01 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","MDCO"],"gpt_icon":0},{"id":"2514021858","title":"Q4 2024 Revolution Medicines Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2514021858","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514021858?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:56","pubTimestamp":1740660988,"startTime":"0","endTime":"0","summary":"Ryan Asay; Senior Vice President, Corporate Affairs; Revolution Medicines Inc. Mark Goldsmith; Chairman of the Board, President, Chief Executive Officer; Revolution Medicines Inc. Steve Kelsey; President - Research and Development; Revolution Medicines Inc. Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 2024 earnings conference call.  Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan Asay. Please go ahead.Thanks, Ryan. Good afternoon and thank you for joining us. Today, I'll cover highlights of progress with our pioneering RAS inhibitor pipeline and outline important priorities for 2025 as well as markers of progress what we expect going forward as we pursue these priorities. Jack Anders will then summarize our financial results and provide a forward-looking financial view. Our mission at Revolution Medicines one that we have pursued for much of our 10-year history","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-revolution-medicines-inc-125628947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RVMDW","RVMD","MDCO"],"gpt_icon":0},{"id":"2514589371","title":"Revolution Medicines Q4 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2514589371","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514589371?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:51","pubTimestamp":1740606667,"startTime":"0","endTime":"0","summary":"Revolution Medicines  reported a Q4 net loss late Wednesday of $1.12 per diluted share, narrowing from a loss of $1.14 a year earlier.Analysts polled by FactSet expected a loss of $1.02The company did not report any revenue for the quarter ended Dec. 31.The company expects its current cash, cash equivalents and marketable securities to fund operations into the second half of 2027.Shares of the compnay were down 2% in recent after-hours activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","RVMD","BK4139"],"gpt_icon":0},{"id":"2514898262","title":"Revolution Medicines Q4 2024 GAAP EPS $(1.12) Misses $(1.00) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898262","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898262?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:29","pubTimestamp":1740605373,"startTime":"0","endTime":"0","summary":"Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(1.00) by 12 percent. This is a 1.75 percent increase over losses of $(1.14) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43990890/revolution-medicines-q4-2024-gaap-eps-1-12-misses-1-00-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","MDCO"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":5,"totalSize":153,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{}}}